

Giacomo Sgalla

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8679864/giacomo-sgalla-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32
papers

540
citations

12
h-index

23
g-index

41
ext. papers

794
ext. citations

5.7
avg, IF

4.12
L-index

#	Paper	IF	Citations
32	Idiopathic pulmonary fibrosis: pathogenesis and management. <i>Respiratory Research</i> , 2018 , 19, 32	7.3	174
31	Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history. <i>Respirology</i> , 2016 , 21, 427-373.6		90
30	Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. <i>JCI Insight</i> , 2016 , 1,	9.9	47
29	Nintedanib for the treatment of idiopathic pulmonary fibrosis. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 167-175	4	36
28	X-ray Micro-Computed Tomography for Nondestructive Three-Dimensional (3D) X-ray Histology. <i>American Journal of Pathology</i> , 2019 , 189, 1608-1620	5.8	24
27	"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease. <i>BMC Pulmonary Medicine</i> , 2018 , 18, 103	3.5	22
26	Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. <i>BMC Medicine</i> , 2015 , 13, 277	11.4	21
25	Novel drug targets for idiopathic pulmonary fibrosis. <i>Expert Review of Respiratory Medicine</i> , 2016 , 10, 393-405	3.8	16
24	Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis. <i>Expert Review of Respiratory Medicine</i> , 2019 , 13, 39-51	3.8	16
23	The safety of new drug treatments for idiopathic pulmonary fibrosis. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1483-1489	4.1	15
22	Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 771-777	5.9	15
21	Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy. <i>BMJ Open Respiratory Research</i> , 2015 , 2, e000065	5.6	13
20	Update in Pulmonary Fibrosis 2018. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 292-300	10.2	6
19	Antibody-based therapies for idiopathic pulmonary fibrosis. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 779-786	5.4	6
18	Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	6
17	Residual respiratory impairment after COVID-19 pneumonia. <i>BMC Pulmonary Medicine</i> , 2021 , 21, 241	3.5	5
16	Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 9-10 ^{10.2}		4

15	Digital Lung Auscultation: Will Early Diagnosis of Fibrotic Interstitial Lung Disease Become a Reality?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, 261-263	10.2	3
14	Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study. <i>Respirology</i> , 2020 , 25, 1144-1151	3.6	3
13	Progressive Fibrosing Interstitial Lung Disease. A Proposed Integrated Algorithm for Management. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 1199-1203	4.7	3
12	COVID-related fibrosis: insights into potential drug targets. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 1-13	5.9	3
11	Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends. <i>BMC Pulmonary Medicine</i> , 2020 , 20, 249	3.5	2
10	An updated safety review of the drug treatments for idiopathic pulmonary fibrosis. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 1035-1048	4.1	2
9	Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2021 , 26, 93-101	3.7	2
8	Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report. <i>Journal of Medical Case Reports</i> , 2016 , 10, 127	1.2	2
7	Management of Idiopathic Pulmonary Fibrosis 2018 , 55-63		1
6	Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	0
5	Phase three clinical trials in idiopathic pulmonary fibrosis. <i>Expert Opinion on Orphan Drugs</i> , 2021 , 9, 1-11	1.1	0
4	Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going. <i>Current Respiratory Care Reports</i> , 2012 , 1, 216-223		
3	Therapeutic approach and molecular targets for novel treatments 2015 , 176-195		
2	Telemedicine-enabled, Hotel-based Management of Patients with COVID-19: A Single-Center Feasibility Study. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1743-1746	4.7	
1	Advances with pharmacotherapy for the treatment of interstitial lung disease.. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 1-13		4